Xingyi Fan's Colleagues at Candel Therapeutics
Xingyi Fan's Contact Details
617-916-5445
Greater Boston
Candel Therapeutics
Xingyi Fan's Company Details
Candel ($CADL) is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel's engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. New discovery programs are based on the HSV platform. For more information, visit www.candeltx.com or contact us at info@candeltx.com.